Charles Kennergren

Charles Kennergren

Auto-generated profile, based on publicly available information

Charles Kennergren

Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
BWBruce L. Wilkoff
Bruce L. Wilkoff
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
SMSuneet Mittal
Suneet Mittal
JPJeanne E. Poole
Jeanne E. Poole
CKCharles Kennergren
Charles Kennergren
KTKhaldoun G. Tarakji
Khaldoun G. Tarakji
Background - In the WRAP-IT trial, adjunctive use of an absorbable antibacterial envelope resulted in a 40% reduction of major cardiac implantable electronic device (CIED) infection without increased risk of complication in 6,983 patients undergoing CIED revision, replacement, upgrade, or initial cardiac resynchronization therapy defibrillator (CRT-D) implant. There is limited information on the cost-effectiveness of this strategy. As a pre-specified objective, we evaluated antibacterial envelope cost-effectiveness compared to standard-of-care infection prevention strategies in the US healthcare system. Methods - A decision tree model was used to compare costs and outcomes of antibacterial envelope (TYRX) use adjunctive to standard-of-care infection prevention vs. standard-of-care alone over a lifelong time horizon. The analysis was performed from an integrated payer-provider network perspective. Infection rates, antibacterial envelope effectiveness, infection treatment costs and patterns, infection-related mortality, and utility estimates were obtained from the WRAP-IT trial. Life expectancy and long-term costs associated with device replacement, follow-up, and healthcare utilization were sourced from the literature. Costs and quality-adjusted life years (QALYs) were discounted at 3%. An upper willingness-to-pay (WTP) threshold of $150,000 per QALY was used to determine cost-effectiveness, in alignment with American College of Cardiology and American Heart Association (ACC/AHA) practice guidelines and as supported by the World Health Organization (WHO) and contemporary literature. Results - The base-case incremental cost-effectiveness ratio (ICER) of the antibacterial envelope compared to standard-of-care was $112,603/QALY. The ICER remained lower than the WTP threshold in 74% of iterations in the probabilistic sensitivity analysis and was most sensitive to the following model inputs: infection-related mortality, life expectancy, and infection cost. Conclusions - The absorbable antibacterial envelope was associated with a cost-effectiveness ratio below contemporary benchmarks in the WRAP-IT patient population, suggesting that the envelope provides value for the US healthcare system by reducing the incidence of CIED infection.

14 August 2013 in Herzschrittmachertherapie + Elektrophysiologie
Verified
Journal Article
Closed access
PDF file
MBMaria Grazia Bongiorni
Maria Grazia Bongiorni
SRSimone L. Romano
Simone L. Romano
CKCharles Kennergren
Charles Kennergren
CBChristian Butter
Christian Butter
JDJean Claude Deharo
Jean Claude Deharo
AAAngelo Auricchio
Angelo Auricchio

18 October 2019 in EP Europace
Verified
Journal Article
Closed access
ENEyal Nof
Eyal Nof
MBMaria Grazia Bongiorni
Maria Grazia Bongiorni
AAAngelo Auricchio
Angelo Auricchio
CBChristian Butter
Christian Butter
NDNikolaos Dagres
Nikolaos Dagres
MGMichael Glikson
Michael Glikson
Aims: The present study sought to determine predictors for success and outcomes of patients who underwent cardiac implantable electronic devices (CIED) extraction indicated for systemic or local CIED related infection in particular where complete lead removal could not be achieved. Methods and results: ESC-EORP ELECTRa (European Lead Extraction ConTRolled Registry) is a European prospective lead extraction registry. Out of the total cohort, 1865/3510 (52.5%) patients underwent removal due to CIED related infection. Predictors and outcomes of failure were analysed. Complete removal was achieved in 1743 (93.5%) patients, partial (4 cm of lead left) in 32 (1.8%) patients. Removal success was unrelated to type of CIED infection (pocket or systemic). Predictors for failure were older leads and older patients [odds ratio (OR) 1.14 (1.08–1.19), P < 0.0001 and OR 2.68 (1.22–5.91), P = 0.0146, respectively]. In analysis by lead, predictors for failure were: pacemaker vs. defibrillator removal and failure to engage the locking stylet all the way to the tip [OR 0.20 (0.04–0.95), P = 0.03 and OR 0.32 (0.13–0.74), P = 0.008, respectively]. Significantly higher complication rates were noted in the failure group (40.6% vs. 15.9 for partial and 8.7% for success groups, P < 0.0001). Failure to remove a lead was a strong predictor for in hospital mortality [hazard ratio of 2.05 (1.01–4.16), P = 0.046]. Conclusion: A total of 6.5% of infected CIED patients failed attempted extraction. Only were >4 cm of lead remained resulted in higher procedural complications and mortality rates.

27 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSimon Pecha
Simon Pecha
CKCharles Kennergren
Charles Kennergren
YYYalin Yildirim
Yalin Yildirim
NGNils Gosau
Nils Gosau
AAAli Aydin
Ali Aydin
SHSamer Hakmi
Samer Hakmi
Implantation of coronary sinus (CS) leads may be a difficult procedure due to different vein anatomies and a possible lead dislodgement. The mode of CS lead fixation has changed and developed in recent years. We compared the removal procedures of active and passive fixation leads. Between January 2009 and January 2014, 22 patients at our centre underwent CS lead removal, 6 active and 16 passive fixation leads were attempted using simple traction or lead locking devices with or without laser extraction sheaths. Data on procedural variables and success rates were collected and retrospectively analyzed. The mean patient age was 67.2 ± 9.8 years, and 90.9% were male. The indication for lead removal was infection in all cases. All active fixation leads were Medtronic® Attain StarFix™ Model 4195 (Medtronic Inc., Minneapolis, MN, USA). The mean time from implantation for the active and passive fixation leads was 9.9 ± 11.7 months (range 1.0–30.1) and 48.7 ± 33.6 months (range 5.7–106.4), respectively (p = 0.012). Only 3 of 6 StarFix leads were successfully removed (50%) compared to 16 of 16 (100%) of the passive fixation CS leads (p = 0.013). No death or complications occurred during the 30-day follow-up. According to our experience, removal of the Starfix active fixation CS leads had a higher procedural failure rate compared to passive.

1 May 2021 in JACC
Verified
Journal Article
Closed access
KTKhaldoun G. Tarakji
Khaldoun G. Tarakji
PKPanagiotis Korantzopoulos
Panagiotis Korantzopoulos
FPFrancois Philippon
Francois Philippon
Mauro BiffiMauro Biffi
Mauro Biffi
SMSuneet Mittal
Suneet Mittal
BWBruce Wilkoff
Bruce Wilkoff

1 June 2005 in EP Europace
Verified
Journal Article
Open access
PDF file
LSL. Sloman
L. Sloman
CKCharles Kennergren
Charles Kennergren
KNKnops
Knops
Mauro BiffiMauro Biffi
Mauro Biffi